Diabetes Market in UAE
Single User PDF Format: US$ 800.00
Multi-User License: US$ 1,200.00
Hard Copy: US$ 900.00
CD-ROM: US$ 900.00
Diabetes is the world’s most costly epidemic. It is anticipated that, over 10% of the population in countries such as, the US, Malaysia, and Indonesia will be diabetic by 2020 and there will be over 300 Million diabetics worldwide. Similarly, the prevalence of diabetes has been increasing in the UAE as well. Diabetes in the UAE is becoming a major health issue with 19-25% of the UAE nationals or one in four people being diabetic. Viewing this, spending of the government as well as consumers has been continuously increasing in the country for the past few years. According to our new research report “Diabetes Market in UAE”, amid increasing spending and prevalence of diabetes, the diabetes market in the country is anticipated to grow at a CAGR of 10% during 2011 - 2013.
We have studied the UAE diabetes market by segmenting it into - oral diabetic drug market, insulin market, and diabetes medical devices market. Medical devices market is further segmented into glucose monitoring market, insulin pump market, insulin pen market, and insulin syringes market. Each of these two segments have been thoroughly studied and analyzed in the report. Moreover, the report provides an overview of patient profile in the country, which will help clients to identify the future demand scenario.
Our report has also found that among the medical devices, insulin pump acquires a major share of the total diabetes market. The main factor responsible for such a sizeable share is the unique capability of the pump of delivering insulin automatically into the body directly. A number of other factors such as, epidemic proportion of diabetes, growing need for efficient control over blood sugar levels, and various insurance plans that include the expenditure of pump and supplies also support the growth of the market.
The report studies the current development process and its effects on various segments of the industry. The research provides detail statistical and analytical review of the macroeconomic indicators, key drivers, and restraints. It contains exhaustive information about the market players, government initiatives, and patients’ profile that will help clients to plan market strategies and assess opportunity areas in the UAE diabetes market.
The report also includes a section of future projection and demand analysis that provides a rough idea about the prospective market trends to facilitate clients’ understanding regarding the future growth of the market.
Multi-User License: US$ 1,200.00
Hard Copy: US$ 900.00
CD-ROM: US$ 900.00
Diabetes is the world’s most costly epidemic. It is anticipated that, over 10% of the population in countries such as, the US, Malaysia, and Indonesia will be diabetic by 2020 and there will be over 300 Million diabetics worldwide. Similarly, the prevalence of diabetes has been increasing in the UAE as well. Diabetes in the UAE is becoming a major health issue with 19-25% of the UAE nationals or one in four people being diabetic. Viewing this, spending of the government as well as consumers has been continuously increasing in the country for the past few years. According to our new research report “Diabetes Market in UAE”, amid increasing spending and prevalence of diabetes, the diabetes market in the country is anticipated to grow at a CAGR of 10% during 2011 - 2013.
We have studied the UAE diabetes market by segmenting it into - oral diabetic drug market, insulin market, and diabetes medical devices market. Medical devices market is further segmented into glucose monitoring market, insulin pump market, insulin pen market, and insulin syringes market. Each of these two segments have been thoroughly studied and analyzed in the report. Moreover, the report provides an overview of patient profile in the country, which will help clients to identify the future demand scenario.
Our report has also found that among the medical devices, insulin pump acquires a major share of the total diabetes market. The main factor responsible for such a sizeable share is the unique capability of the pump of delivering insulin automatically into the body directly. A number of other factors such as, epidemic proportion of diabetes, growing need for efficient control over blood sugar levels, and various insurance plans that include the expenditure of pump and supplies also support the growth of the market.
The report studies the current development process and its effects on various segments of the industry. The research provides detail statistical and analytical review of the macroeconomic indicators, key drivers, and restraints. It contains exhaustive information about the market players, government initiatives, and patients’ profile that will help clients to plan market strategies and assess opportunity areas in the UAE diabetes market.
The report also includes a section of future projection and demand analysis that provides a rough idea about the prospective market trends to facilitate clients’ understanding regarding the future growth of the market.
1. ANALYST VIEW
2. RESEARCH METHODOLOGY
3. MARKET OVERVIEW
4. PATIENT PROFILE ANALYSIS
5. DIABETES MARKET FORECAST TO 2013
5.1 By Type
5.1.1 Oral Diabetic Drug Market
5.1.2 Insulin Market
5.2 By Delivery Devices
5.2.1 Insulin Pump
5.2.2 Insulin Pen
5.2.3 Insulin Syringes
5.3 By Monitoring
5.3.1 Glucose Monitoring
6. GOVERNMENT INITIATIVES
7. KEY PLAYERS
7.1 Novo Nordisk
7.2 Bayer HealthCare
7.3 Sanofi Aventis
7.4 Medysinal Fze
2. RESEARCH METHODOLOGY
3. MARKET OVERVIEW
4. PATIENT PROFILE ANALYSIS
5. DIABETES MARKET FORECAST TO 2013
5.1 By Type
5.1.1 Oral Diabetic Drug Market
5.1.2 Insulin Market
5.2 By Delivery Devices
5.2.1 Insulin Pump
5.2.2 Insulin Pen
5.2.3 Insulin Syringes
5.3 By Monitoring
5.3.1 Glucose Monitoring
6. GOVERNMENT INITIATIVES
7. KEY PLAYERS
7.1 Novo Nordisk
7.2 Bayer HealthCare
7.3 Sanofi Aventis
7.4 Medysinal Fze
LIST OF FIGURES:
Figure 4-1: Prevalence of Diabetes (%), 2010 & 2030
Figure 4-2: Prevalence of Impaired Glucose Tolerance (%), 2010 & 2030
Figure 4-3: Number of Diabetic Population (‘000), 2010-2012
Figure 5-1: Diabetes Market (Million US$), 2010-2013
Figure 5-2: Diabetes Market by Segment (%), 2010
Figure 5-3: Oral Diabetic Drug Market (Million US$), 2010-2013
Figure 5-4: Insulin Market (Million US$), 2010-2013
Figure 5-5: Insulin Pump Market (Million US$), 2010-2013
Figure 5-6: Insulin Pen Market (Million US$), 2010-2013
Figure 5-7: Insulin Syringe Market (Million US$), 2010-2013
Figure 5-8: Gluco Meter Market (Million US$), 2010-2013
LIST OF TABLE:
Table 4-1: Prevalence of Obesity by BMI (%), 2005
Figure 4-1: Prevalence of Diabetes (%), 2010 & 2030
Figure 4-2: Prevalence of Impaired Glucose Tolerance (%), 2010 & 2030
Figure 4-3: Number of Diabetic Population (‘000), 2010-2012
Figure 5-1: Diabetes Market (Million US$), 2010-2013
Figure 5-2: Diabetes Market by Segment (%), 2010
Figure 5-3: Oral Diabetic Drug Market (Million US$), 2010-2013
Figure 5-4: Insulin Market (Million US$), 2010-2013
Figure 5-5: Insulin Pump Market (Million US$), 2010-2013
Figure 5-6: Insulin Pen Market (Million US$), 2010-2013
Figure 5-7: Insulin Syringe Market (Million US$), 2010-2013
Figure 5-8: Gluco Meter Market (Million US$), 2010-2013
LIST OF TABLE:
Table 4-1: Prevalence of Obesity by BMI (%), 2005
